

**UNITED STATES DEPARTMENT OF COMMERCE****United States Patent and Trademark Office**

Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

*Cal*

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
09/593,793	06/13/00	XU	J 210121.427C1

000500 HMI270727  
SEED INTELLECTUAL PROPERTY LAW GROUP PLL  
701 FIFTH AVE  
SUITE 6300  
SEATTLE WA 98104-7092

EXAMINER
----------

TAYLOR, J

ART UNIT	PAPER NUMBER
1655	10

DATE MAILED:

07/27/01

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

# Office Action Summary

Application No.

09/593,793

Applicant(s)

XU ET AL

Examiner

Janell Taylor Cleveland

Art Unit

1655

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

## Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

## Status

- 1) ☐ Responsive to communication(s) filed on \_\_\_\_\_.
- 2a) ☐ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

## Disposition of Claims

- 4) ☒ Claim(s) 1-60 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☐ Claim(s) \_\_\_\_\_ is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☒ Claim(s) 1-60 are subject to restriction and/or election requirement.

## Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on \_\_\_\_\_ is: a) ☐ approved b) ☐ disapproved by the Examiner.
- If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

## Priority under 35 U.S.C. §§ 119 and 120

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- \* See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
- a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

## Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s) \_\_\_\_\_
- 4) ☐ Interview Summary (PTO-413) Paper No(s). \_\_\_\_\_
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other:

**DETAILED ACTION**

***Election/Restrictions***

1. Restriction to one of the following inventions is required under 35-U.S.C. 121: - - - - -
  - I. Claims 1-3, drawn to a polypeptide, classified in class 530, subclass 350.
  - II. Claims 4-10, and 58-60, drawn to polynucleotides and kits thereof, classified in class 435, subclass 6.
  - III. Claims 11 and 54-57, drawn to antibodies and kits thereof, classified in class 424, subclass 130.1.
  - IV. Claims 12-16, drawn to fusion proteins, classified in class 530, subclass 402.
  - V. Claims 17, 21, and 23, drawn to pharmaceutical compositions, classified in class 514, subclass 2.
  - VI. Claims 18-20, 22, 25-31, drawn to immunogenic compositions, classified in class 424, subclass 130.1.
  - VII. Claims 32-33 and 34, drawn to methods for removing tumor cells, classified in class 435, subclass 1.1.
  - VIII. Claims 35-37, drawn to methods for stimulating and/or expanding T-cells, classified in class 424, subclass 184.1.
  - IX. Claims 38-39, drawn to method for inhibiting the development of cancer in a patient, classified in class 514, subclass 2.
  - X. Claims 40-43, and 48-50, drawn to methods for determining the presence or absence of cancer in a patient, classified in class 435, subclass 4.

XI. Claims 44-47, 51-53, drawn to methods for monitoring the progression of cancer in a patient, classified in class 435, subclass 4.

The inventions are distinct, each from the other because of the following reasons:

1. Inventions I and II are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions are drawn to a nucleic acid and a protein, which have different functions, i.e., the nucleic acid codes for protein and the protein is used for various purposes in the cell, in the instant case as prostate-specific proteins. The nucleic acid is capable of functioning to code for a peptide without the peptide being present, and can be used by the practitioner to create probes, primers, and for diagnostic purposes without the presence of the peptide. Furthermore, the peptide is capable of functioning without the nucleic acid being present in the cell.
2. Inventions I, II and III are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions are drawn to nucleic acids, proteins and antibodies. The antibodies have different functions in the cell than either the protein or the nucleic acid, and are used for immunological purposes.
3. Inventions I-III and IV are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In

Art Unit: 1655

the instant case the different inventions are drawn to nucleic acids, proteins, antibodies, and pharmaceutical compositions. While the first three are naturally occurring in the cell, pharmaceutical compositions are created for use in ameliorating disease, and therefore has a different effect.

4. Inventions I-IV and V are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions are drawn to nucleic acids, proteins, antibodies, pharmaceutical compositions, and fusion proteins. Fusion proteins have different functions and different effects in the cell, and are capable of use without the other products.

5. Inventions I-V and VI-XI are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the methods of use do not require that the product be present, as they are capable of working with any known polypeptide/polynucleotide/antibody, and the products are capable of use without the methods.

6. Inventions X and XI are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In

Art Unit: 1655

the instant case the different inventions have different modes of operation, as one monitors the progress of cancer, and one simply detects the presence or absence of cancer.

7. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper.

8. Because these inventions are distinct for the reasons given above and the search required for Group I is not required for Group II-XI, etc, restriction for examination purposes as indicated is proper.

***Sequence Election Requirement Applicable to All Groups***

In addition, some of the claims detailed above read on patentably distinct Groups drawn to multiple SEQ ID Numbers. The sequences are patentably distinct because they are unrelated sequences, and a further restriction is applied to the sequences. For an elected Group drawn to amino acid sequences, the Applicants must further elect a single amino acid sequence. For an elected Group drawn to nucleotide sequences, the Applicants are permitted to elect up to 10 nucleic acid sequences (See MPEP 803.04).

MPEP 803.04 states:

Nucleotide sequences encoding different proteins are structurally distinct chemical compounds and are unrelated to one another. These sequences are thus deemed to normally constitute independent and distinct inventions within the meaning of 35 U.S.C. 121. Absent evidence to the contrary, each such nucleotide sequence is presumed to represent an independent and distinct invention, subject to a restriction requirement pursuant to 35 U.S.C. 121 and 37 CFR 1.141 et seq. Nevertheless, to further aid the biotechnology industry in protecting its intellectual property without creating an undue burden on the Office, the Commissioner has decided sua sponte to partially waive the requirements of 37 CFR 1.141 et seq. and permit a reasonable number of such nucleotide sequences to be claimed in a single application. See

Art Unit: 1655

Examination of Patent Applications Containing Nucleotide Sequences, 1192 O.G. 68 (November 19, 1996).

It has been determined that normally ten sequences constitute a reasonable number for examination purposes. Accordingly, in most cases, up to ten independent and distinct nucleotide sequences will be examined in a single application without restriction. In addition to the specifically selected sequences, those sequences which are patentably indistinct from the selected sequences will also be examined. Furthermore, nucleotide sequences encoding the same protein are not considered to be independent and distinct inventions and will continue to be examined together.

*Although the MPEP deems that up to ten nucleotide sequences may be searched without restriction, it has recently been decided by the Director of Biotechnology at the USPTO that searching more than one sequence per application will place an undue burden upon the Examiner and the Office. For this reason, restriction to ONE SEQUENCE is being applied to all applications at this time.*

9. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Janell Taylor Cleveland whose telephone number is 703-305-0273. The examiner can normally be reached on M-F 9-6.


Art Unit: 1655

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Jones can be reached on 703-308-1152. The fax phone numbers for the organization where this application or proceeding is assigned are 703-308-8724 for regular communications and 703-308-8724 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

Janell Taylor Cleveland  
Examiner  
Art Unit 1655

July 24, 2001

  
CARLA J. MYERS  
PRIMARY EXAMINER